Expansion Opportunity Metrion is doubling its laboratory space and expanding facilities at Granta Park Cambridge, signaling ongoing growth and increased project throughput. This creates potential for upsell of integrated preclinical services, larger scale electrophysiology studies, and expanded CRO collaboration with existing and new partners.

European Focus Recent leadership hire for Europe and notable European facility expansion indicate a strategic emphasis on the European market. Sales opportunities exist in partnering with European biotech and pharma clients seeking ion channel screening, cardiac safety, and neuroscience assays within close geographic support.

Clinical Readiness Strong track record in ion channel screening, high-throughput assays, and translational cardiac safety studies positions Metrion as a preferred partner for companies needing reliable preclinical data to de-risk programs before IND filings, especially in ion channel–related therapeutic areas.

Industry Recognition Awards for Campaign of the Year and active engagement in industry events demonstrate credibility and visibility. Leverage these accolades to approach prospective clients with social proof, case studies, and talking points that highlight successful collaborations and outcomes.

Team Expertise Leadership and senior scientists bring extensive drug discovery experience focused on ion channels, supported by 150 publications. This depth can be translated into differentiated partner narratives around data quality, interpretation, and actionable recommendations for complex projects.